Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
Date:10/30/2008

ent (R&D) expenses in the third quarter of 2008 were $24.5 million, compared to $27.6 million in the prior year period, a decrease of 11% that resulted primarily from the purchase of human papillomavirus (HPV) oligonucleotides from Roche in the prior year period. For the first nine months of 2008, R&D expenses were $76.9 million, compared to $72.8 million in the prior year period, an increase of 6% that resulted primarily from costs associated with key development programs such as the post-marketing studies of the PROCLEIX ULTRIO assay in the United States, the investigational APTIMA human papillomavirus (HPV) assay, and Gen-Probe's fully automated instrument system for low- and mid-volume labs, known as PANTHER.

Marketing and sales expenses in the third quarter of 2008 were $10.7 million, compared to $9.7 million in the prior year period, an increase of 10% that resulted primarily from European market development efforts related to the Company's APTIMA Combo 2, APTIMA HPV and PROGENSATM PCA3 assays. For the first nine months of 2008, marketing and sales expenses were $34.1 million, compared to $28.6 million in the prior year period, an increase of 19%.

General and administrative (G&A) expenses in the third quarter of 2008 were $12.9 million, compared to $11.4 million in the prior year period, an increase of 13% that resulted primarily from increased compensation and legal costs. For the first nine months of 2008, G&A expenses were $38.5 million, compared to $34.7 million in the prior year period, an increase of 11%.

Total other income in the third quarter of 2008 was $2.2 million, compared to $3.3 million in the prior year period, a decrease of 33% that resulted primarily from a $1.6 million impairment charge associated with the Company's equity investment in Qualigen, Inc. The Company reviews its investments regularly and records impairment charges when an investment has experienced a decline that is expected to be other-than temporary. For th
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
4. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
5. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
6. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
8. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
9. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Nuvelo Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 30, 2014 Hundreds of Byetta lawsuits ... to move forward in U.S. courts, Bernstein Liebhard LLP ... on July 31, 2014, Byetta and Bydureon (an extended-release ... liability claims that allege the drugs caused pancreatitis, pancreatic ... of these claims are pending in a multidistrict litigation ...
(Date:8/30/2014)... Springs, CO (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) rob people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Lab Oven including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Spanish . , The " La Mente Bilinge " ... Arts at the University of the Basque Country analyses bilingual processing ... acquires and manages languages and to discover in what way languages ... In order to understand how we become fluent in a language ...
... make healthy choices, study shows , , MONDAY, June 30 (HealthDay News) ... serving of baked or fried food bad for you, or can ... no amount of the artery-clogging artificial fat is good for ... panel found on the side of grocery store products does a ...
... on Outstanding Quality and Compliance -, LEXINGTON, ... that it has received the prestigious Supplier,Performance Award ... The,award recognizes outstanding performance in quality and compliance ... as award winners. IL,was presented with the honor ...
... WEST CONSHOHOCKEN, Pa., June 30 Cadient Group, ... today announced that Stephen Wray, President and CEO ... Young Entrepreneur Of The Year(R) in the,Greater Philadelphia ... program,was designed to recognize outstanding entrepreneurs on a ...
... MUMBAI, India, June 30 Sun Pharmaceutical,Industries Ltd. ... today announced that Alkaloida Chemical Company Exclusive Group,Ltd. ... a tender offer,for all outstanding Ordinary Shares of ... share in cash., On May 18, 2007, ...
... Health Solutions Corp.,("SXC" or the "Company") (NASDAQ: ... and pharmacy benefits management services, announces a five ... benefit management,("PBM") services with The University of Toledo ... for more than 6,000 members of,UT,s employee prescription ...
Cached Medicine News:Health News:Laka: 'Language exists in the brain' 2Health News:Laka: 'Language exists in the brain' 3Health News:Laka: 'Language exists in the brain' 4Health News:Trans Fat Labeling Gets Tricky 2Health News:Trans Fat Labeling Gets Tricky 3Health News:Trans Fat Labeling Gets Tricky 4Health News:Trans Fat Labeling Gets Tricky 5Health News:Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 3Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 2Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 3Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical ... Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it ... to address a potential issue with a clip ... the Axilla application of the SAM Junctional Tourniquet ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
Medicine Products: